Scarica l'app Stockscreener
120.87
0.02%
0.03
Dopo l'orario di chiusura:
120.87
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Merck Co Inc Borsa (MRK) Ultime notizie
Nvwm LLC Acquires 31,854 Shares of Merck & Co., Inc. $MRK - MarketBeat
JB Capital LLC Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Stock Position Trimmed by Florida Trust Wealth Management Co - MarketBeat
Perpetual Ltd Purchases 9,261 Shares of Merck & Co., Inc. $MRK - MarketBeat
SS&H Financial Advisors Inc. Acquires 12,200 Shares of Merck & Co., Inc. $MRK - MarketBeat
SteelPeak Wealth LLC Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Quintet Private Bank Europe S.A. - MarketBeat
Leerink raises Merck & Co. Inc. (MRK) price target, sees upside from cancer drug - MSN
Merck & Co., Inc. stock: Steady performer amid healthcare shifts - AD HOC NEWS
Erste Group Initiates Merck & Co(MRK.US) With Hold Rating - Moomoo
West Branch Capital LLC Sells 15,875 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. stock: Strong margins amid shifting pharma winds - ad-hoc-news.de
Eldred Rock Partners LLC Has $11.31 Million Stake in Merck & Co., Inc. $MRK - MarketBeat
10,200 Shares in Merck & Co., Inc. $MRK Purchased by FNY Investment Advisers LLC - MarketBeat
16,300 Shares in Merck & Co., Inc. $MRK Purchased by Dorato Capital Management - MarketBeat
Empirical Financial Services LLC d.b.a. Empirical Wealth Management Grows Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Aberdeen Group plc - MarketBeat
Merck & Co., Inc. stock: A cornerstone of pharmaceutical innovation and dividend reliability for lon - AD HOC NEWS
FinancialContentMerck’s Oncology Empire Expands: Keytruda Secures Pivotal European Commission Approval for Recurrent Ovarian Cancer - markets.financialcontent.com
Merck Just Made a Big Bet on a New Cancer Growth Engine - Investing.com
Merck initiates Phase 2b/3 trial for treatment of age-related macular degeneration - ROI-NJ
Merck Announces Initiation of Pivotal Phase 2B/3 Trial Evaluating Mk-8748 for Treatment of Neovascular Age-Related Macular Degeneration - MarketScreener
Merck & Co Inc (MEX:MRK) Stock Price, Trades & News - gurufocus.com
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investiga - PharmiWeb.com
Merck & Co. (MRK) Announces Detailed Results From the Phase 2 CADENCE Study - Insider Monkey
Merck's (MRK) Keytruda Gains Fast Track Status in Colorectal Can - gurufocus.com
Chongqing Zhifei Biological Products adjusts cooperation agreement with Merck & Co - MarketScreener
Merck wins EU nod for Keytruda combo in ovarian cancer (MRK) - Seeking Alpha
Merck (MRK) Gains EU Approval for Keytruda Regimen in Ovarian Ca - GuruFocus
Merck (MRK) Advances MK-8748 Trial for Eye Disease Treatment - GuruFocus
Merck Says EU Approves Keytruda Combination Regimen for Platinum-Resistant Ovarian Cancer - MarketScreener
Merck Announces Initiation of Pivotal Phase 2b/3 Trial Evaluating MK-8748 (Tiespectus), an Investigational Bispecific Tie2 Agonist/VEGF Inhibitor, for the Treatment of Neovascular Age-Related Macular Degeneration - Business Wire
Tema Etfs LLC Raises Stock Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Purchased by Compagnie Lombard Odier SCmA - MarketBeat
Bank Pictet & Cie Europe AG Lowers Stake in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Banque Pictet & Cie SA - MarketBeat
Merck (MRK) Reports Strong Phase 3 Results for Oral PCSK9 - Insider Monkey
Startup Infinimmune sees close to $1 billion, validation in big Merck drug dealSan Francisco Business Times - The Business Journals
Merck (NYSE: MRK) director receives new cash-settled phantom stock grant - Stock Titan
Merck (MRK) director Glocer granted 405 phantom stock units, holds 5,100 shares - Stock Titan
Merck (NYSE: MRK) director granted new phantom stock units - Stock Titan
Merck & Co deal worth up to $838 million to Infinimmune - The Pharma Letter
What's Going On With Merck Stock Wednesday?Merck & Co (NYSE:MRK) - Benzinga
Vaughan Nelson Investment Management L.P. Sells 11,515 Shares of Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Sold by Highline Wealth Partners LLC - MarketBeat
Merck to Hold First-Quarter 2026 Sales and Earnings Conference Call April 30 - Business Wire
Nisa Investment Advisors LLC Increases Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co., Inc. $MRK Shares Bought by Moody Lynn & Lieberson LLC - MarketBeat
Shrier Wealth Management LLC Buys New Position in Merck & Co., Inc. $MRK - MarketBeat
Advanced Renal Cell Carcinoma Treatment Market to Grow by $3.1 Billion During 2026-2030: Global Industry Assessment Featuring Pfizer, Merck & Co., Bristol-Myers Squibb, AstraZeneca, Novartis and More - Yahoo Finance
Econ Financial Services Corp Sells 8,757 Shares of Merck & Co., Inc. $MRK - MarketBeat
Allspring Global Investments Holdings LLC Has $96.05 Million Holdings in Merck & Co., Inc. $MRK - MarketBeat
Merck & Co Inc (6MK.HA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Merck (MRK) Gains But Lags Market: What You Should Know - Yahoo Finance
Merck & Co. Inc. stock rises Tuesday, still underperforms market - MarketWatch
Merck Does Not See Fasting Requirement Limiting Uptake For Enlicitide - Citeline News & Insights
Why is Merck & Co. (MRK) One of the Best Affordable Stocks to Buy With Good Earnings Growth? - Insider Monkey
Goldman Sachs Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $133 - moomoo.com
Merck strikes deal with antibody discovery startup - BioPharma Dive
Infinimmune Enters Collaboration with Merck to Discover Novel Human Antibody Therapeutics - Business Wire
Merck Just Made a Big Bet on a New Cancer Growth Engine - MarketBeat
Westend Capital Management LLC Boosts Holdings in Merck & Co., Inc. $MRK - MarketBeat
0.68%
1.37%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):